Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC) at this year’s virtual ASCO 2020.
Moshe Ornstein, MD on Phase 1B Trial of Neoadjuvant/adjuvant Durvalumab: Why are the rates of Toxicity Higher than Expected? #ASCO2020 @MosheOrnsteinMD #ASCO @ClevelandClinic
By Editor